e73
c5b
c72
bc1
cb7
f9c
cbc
c56
dae
a40
e1e
d07
db8
f32
f9c
d07
f9c
bb9
dfd
aa8
c78
db7
c78
e4a
a76
ca8
e08
d78
b20
c4a
f2c
f1d
a65
b37
a44
f50
d31
fdd
d65
a3e
fdd
a3e
d65
d31
fca
ee6
b99
af0
c7d
a33
ed4
baa
da0
eec
a7a
e1a
e0b
f4d
aad
f64
a6c
ec3
d83
d10
f4d
f8b
e86
11733188
PubMed
The binding affinity of HMG1 protein to DNA modified by cis-platin and its analogs correlates with their antitumor activity.
Int J Biochem Cell Biol
2002
Pasheva EA
Ugrinova I
Spassovska NC
Pashev IG
15213293
PubMed
Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B.
Mol Pharmacol
2004
Samimi G
Katano K
Holzer AK
Safaei R
Howell SB
11761458
PubMed
In vitro studies on the mechanisms of oxaliplatin resistance.
Cancer Chemother Pharmacol
2001
Hector S
Bolanowska-Higdon W
Zdanowicz J
Hitt S
Pendyala L
12215535
PubMed
The SWI/SNF chromatin-remodeling factor stimulates repair by human excision nuclease in the mononucleosome core particle.
Mol Cell Biol
2002
Hara R
Sancar A
12504667
PubMed
Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines.
Eur J Cancer
2003
Arnould S
Hennebelle I
Canal P
Bugat R
Guichard S
10810335
PubMed
Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells.
Anticancer Res
2000
Li Q
Yu JJ
Mu C
Yunmbam MK
Slavsky D
Cross CL
Bostick-Bruton F
Reed E
10074455
PubMed
Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours.
Curr Biol
1999
Köberle B
Masters JR
Hartley JA
Wood RD
15269138
PubMed
Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells.
Clin Cancer Res
2004
Samimi G
Safaei R
Katano K
Holzer AK
Rochdi M
Tomioka M
Goodman M
Howell SB
16267001
PubMed
A role for polymerase eta in the cellular tolerance to cisplatin-induced damage.
Cancer Res
2005
Albertella MR
Green CM
Lehmann AR
O'Connor MJ
16951202
PubMed
Organic cation transporters are determinants of oxaliplatin cytotoxicity.
Cancer Res
2006
Zhang S
Lovejoy KS
Shima JE
Lagpacan LL
Shu Y
Lapuk A
Chen Y
Komori T
Gray JW
Chen X
Lippard SJ
Giacomini KM
12839578
PubMed
Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin.
J Invest Dermatol
2003
Liedert B
Materna V
Schadendorf D
Thomale J
Lage H
10626357
PubMed
Specificity of platinum-DNA adduct repair.
J Inorg Biochem
1999
Chaney SG
Vaisman A
16879751
PubMed
Mismatch repair and treatment resistance in ovarian cancer.
BMC Cancer
2006
Helleman J
van Staveren IL
Dinjens WN
van Kuijk PF
Ritstier K
Ewing PC
van der Burg ME
Stoter G
Berns EM
7777511
PubMed
DNA polymerase beta bypasses in vitro a single d(GpG)-cisplatin adduct placed on codon 13 of the HRAS gene.
Proc Natl Acad Sci U S A
1995
Hoffmann JS
Pillaire MJ
Maga G
Podust V
Hübscher U
Villani G
14676106
PubMed
Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients.
Clin Cancer Res
2003
Samimi G
Varki NM
Wilczynski S
Safaei R
Alberts DS
Howell SB
10777605
PubMed
The efficiency and fidelity of translesion synthesis past cisplatin and oxaliplatin GpG adducts by human DNA polymerase beta.
J Biol Chem
2000
Vaisman A
Chaney SG
11323161
PubMed
Up-regulation of transporters of the MRP family by drugs and toxins.
Toxicol Lett
2001
Schrenk D
Baus PR
Ermel N
Klein C
Vorderstemann B
Kauffmann HM
10769112
PubMed
Efficient translesion replication past oxaliplatin and cisplatin GpG adducts by human DNA polymerase eta.
Biochemistry
2000
Vaisman A
Masutani C
Hanaoka F
Chaney SG
15014021
PubMed
Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer.
Clin Cancer Res
2004
Yoh K
Ishii G
Yokose T
Minegishi Y
Tsuta K
Goto K
Nishiwaki Y
Kodama T
Suga M
Ochiai A
15229296
PubMed
The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells.
Mol Pharmacol
2004
Holzer AK
Samimi G
Katano K
Naerdemann W
Lin X
Safaei R
Howell SB
16213010
PubMed
MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma.
Gynecol Oncol
2006
Guminski AD
Balleine RL
Chiew YE
Webster LR
Tapner M
Farrell GC
Harnett PR
Defazio A
8481916
PubMed
Effects of cisplatin on the induction of apoptosis in proliferating hepatoma cells and nonproliferating immature thymocytes.
Cancer Res
1993
Evans DL
Dive C
9816141
PubMed
Immunohistochemical staining for glutathione S-transferase predicts response to platinum-based chemotherapy in head and neck cancer.
Clin Cancer Res
1996
Nishimura T
Newkirk K
Sessions RB
Andrews PA
Trock BJ
Rasmussen AA
Montgomery EA
Bischoff EK
Cullen KJ
8702663
PubMed
Cisplatin and adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line.
J Biol Chem
1996
Drummond JT
Anthoney A
Brown R
Modrich P
12216079
PubMed
Copper-transporting P-type adenosine triphosphatase (ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma: comparative analysis with expression of MDR1, MRP1, MRP2, LRP and BCRP.
Int J Cancer
2002
Nakayama K
Kanzaki A
Ogawa K
Miyazaki K
Neamati N
Takebayashi Y
16847145
PubMed
Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin.
Mol Pharmacol
2006
Holzer AK
Manorek GH
Howell SB
10856253
PubMed
Mechanisms of accurate translesion synthesis by human DNA polymerase eta.
EMBO J
2000
Masutani C
Kusumoto R
Iwai S
Hanaoka F
10811891
PubMed
Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin.
Proc Natl Acad Sci U S A
2000
He Q
Liang CH
Lippard SJ
12370763
PubMed
Evaluation of NQO1 gene expression and variant allele in human NSCLC tumors and matched normal lung tissue.
Int J Oncol
2002
Kolesar JM
Pritchard SC
Kerr KM
Kim K
Nicolson MC
McLeod H
15095299
PubMed
Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines.
Int J Cancer
2004
Welsh C
Day R
McGurk C
Masters JR
Wood RD
Köberle B
2223389
PubMed
Activation of programmed cell death by anticancer agents: cisplatin as a model system.
Cancer Cells
1990
Eastman A
11077043
PubMed
Increased mRNA levels of xeroderma pigmentosum complementation group B (XPB) and Cockayne's syndrome complementation group B (CSB) without increased mRNA levels of multidrug-resistance gene (MDR1) or metallothionein-II (MT-II) in platinum-resistant human ovarian cancer tissues.
Biochem Pharmacol
2000
Dabholkar M
Thornton K
Vionnet J
Bostick-Bruton F
Yu JJ
Reed E
12438251
PubMed
Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper.
Cancer Res
2002
Katano K
Kondo A
Safaei R
Holzer A
Samimi G
Mishima M
Kuo YM
Rochdi M
Howell SB
12578393
PubMed
Translesion synthesis past platinum DNA adducts by human DNA polymerase mu.
Biochemistry
2003
Havener JM
Nick McElhinny SA
Bassett E
Gauger M
Ramsden DA
Chaney SG
16297532
PubMed
Role of copper transporters in the uptake and efflux of platinum containing drugs.
Cancer Lett
2006
Safaei R
20153885
PubMed
Mismatch repair status and outcomes after adjuvant therapy in patients with surgically staged endometrial cancer.
Gynecol Oncol
2010
Resnick KE
Frankel WL
Morrison CD
Fowler JM
Copeland LJ
Stephens J
Kim KH
Cohn DE
16267001
PubMed
A role for polymerase eta in the cellular tolerance to cisplatin-induced damage.
Cancer Res
2005
Albertella MR
Green CM
Lehmann AR
O'Connor MJ
11129735
PubMed
Expression of myeloperoxidase in the inner ear of cisplatin-treated guinea pigs.
Anticancer Drugs
2000
Watanabe K
Yagi T
15173214
PubMed
XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.
J Clin Oncol
2004
Gurubhagavatula S
Liu G
Park S
Zhou W
Su L
Wain JC
Lynch TJ
Neuberg DS
Christiani DC
15534626
PubMed
Interethnic variability of ERCC2 polymorphisms.
Pharmacogenomics J
2005
King CR
Yu J
Freimuth RR
McLeod HL
Marsh S
12391279
PubMed
The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae.
Mol Pharmacol
2002
Lin X
Okuda T
Holzer A
Howell SB
12531023
PubMed
Survival and SOS induction in cisplatin-treated Escherichia coli deficient in Pol II, RecBCD and RecFOR functions.
DNA Repair (Amst)
2002
Bhattacharya R
Beck DJ
11751380
PubMed
11751380
PubMed
11751380
PubMed
A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer.
Cancer Res
2001
Park DJ
Stoehlmacher J
Zhang W
Tsao-Wei DD
Groshen S
Lenz HJ
8674066
PubMed
Loss of DNA mismatch repair in acquired resistance to cisplatin.
Cancer Res
1996
Aebi S
Kurdi-Haidar B
Gordon R
Cenni B
Zheng H
Fink D
Christen RD
Boland CR
Koi M
Fishel R
Howell SB
8040325
PubMed
Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy.
J Clin Invest
1994
Dabholkar M
Vionnet J
Bostick-Bruton F
Yu JJ
Reed E
11605050
PubMed
Expression and cisplatin sensitivity of copper-transporting P-type adenosine triphosphatase (ATP7B) in human solid carcinoma cell lines.
Oncol Rep
2001
Nakayama K
Miyazaki K
Kanzaki A
Fukumoto M
Takebayashi Y
11712813
PubMed
A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer.
Anticancer Res
2001
Stoehlmacher J
Ghaderi V
Iobal S
Groshen S
Tsao-Wei D
Park D
Lenz HJ
1960995
PubMed
Tumor necrosis factor-alpha alters response of lung cancer cells to oxidative stress.
J Thorac Cardiovasc Surg
1991
Pogrebniak HW
Prewitt TW
Matthews WA
Pass HI
15968547
PubMed
Augmented expression of metallothionein and glutathione S-transferase pi as unfavourable prognostic factors in cisplatin-treated ovarian cancer patients.
Virchows Arch
2005
Surowiak P
Materna V
Kaplenko I
Spaczyński M
Dietel M
Lage H
Zabel M
12072547
PubMed
Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer.
J Natl Cancer Inst
2002
Stoehlmacher J
Park DJ
Zhang W
Groshen S
Tsao-Wei DD
Yu MC
Lenz HJ
15916927
PubMed
Role of high mobility group (HMG) chromatin proteins in DNA repair.
DNA Repair (Amst)
2005
Reeves R
Adair JE
15634647
PubMed
Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells.
Mol Cancer Ther
2004
Song IS
Savaraj N
Siddik ZH
Liu P
Wei Y
Wu CJ
Kuo MT
12851839
PubMed
Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome.
Int J Clin Oncol
2003
Medeiros R
Pereira D
Afonso N
Palmeira C
Faleiro C
Afonso-Lopes C
Freitas-Silva M
Vasconcelos A
Costa S
Osório T
Lopes C
10709094
PubMed
Role of metallothionein in cisplatin sensitivity of germ-cell tumours.
Int J Cancer
2000
Meijer C
Timmer A
De Vries EG
Groten JP
Knol A
Zwart N
Dam WA
Sleijfer DT
Mulder NH
16428501
PubMed
DNA polymerase zeta accounts for the reduced cytotoxicity and enhanced mutagenicity of cisplatin in human colon carcinoma cells that have lost DNA mismatch repair.
Clin Cancer Res
2006
Lin X
Trang J
Okuda T
Howell SB
10422815
PubMed
Cisplatin-resistant bladder carcinoma cells: enhanced expression of metallothioneins.
Urol Res
1999
Siegsmund MJ
Marx C
Seemann O
Schummer B
Steidler A
Toktomambetova L
Köhrmann KU
Rassweiler J
Alken P
20017670
PubMed
Genetic polymorphisms in GST genes and survival of colorectal cancer patients treated with chemotherapy.
Pharmacogenomics
2010
Funke S
Timofeeva M
Risch A
Hoffmeister M
Stegmaier C
Seiler CM
Brenner H
Chang-Claude J
8824498
PubMed
Microsatellite instability differences between familial and sporadic ovarian cancers.
Carcinogenesis
1996
Arzimanoglou II
Lallas T
Osborne M
Barber H
Gilbert F